Key result
One-stage and chromogenic FVIII:C assays yield discordant results in ~20% of mild haemophilia A.
Observational (n=163)
Answers are grounded in this paper and cite their sources.
The discrepancy of the levels of factor VIII activity (FVIII:C) by different assays in some mild and moderate haemophilic A patients has been long known. Specific mutations affecting FVIII:C discrepancies have been described. No consensus exit as to which method most accurately represents the FVIII cofactor function in vivo and which has a better correlation with the haemorrhagic clinical expression. We studied 163 mild A haemophiliacs, and detected discrepancies in 20% of the patients, most of whom presented higher levels of FVIII:C with the one-stage assay. In nine families, the FVIII mutation was found, while three showed mutations not previously described (Leu1978Phe and Ser1791Pro associated with higher levels of FVIII:C by one-stage method; Arg1639His in a patient with low level of FVIII:C by the one-stage, but normal, chromogenic assay). Assessing the level of FVIII:C by different methods could help to learn the possible haemorrhagic expressions of patients.
No takes yet. Share an insight, caveat, or question.
Cid et al. (2008) conducted an observational in Mild haemophilia A (n=163). One-stage FVIII:C assay vs. Chromogenic FVIII:C assay was evaluated on FVIII:C assay discrepancy between one-stage and chromogenic methods. One-stage versus chromogenic FVIII:C assay testing detected discrepancies in 20% of 163 mild haemophilia A patients, most showing higher levels with the one-stage assay.
Synapse has enriched 5 related papers. Consider them for comparative context: